Patents by Inventor Xiaohu Deng

Xiaohu Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF A MENIN INHIBITOR
    Publication number: 20250101035
    Abstract: Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 27, 2025
    Inventors: Roger Paul BAKALE, Craig Michael BOWE, Dipanjan SENGUPTA, Patricia Andres, Xiaohu DENG
  • HDAC inhibitor solid state forms
    Patent number: 12012396
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: June 18, 2024
    Assignee: Viracta Subsidiary, Inc.
    Inventors: Xiaohu Deng, Wanping Mai, Robert C. McRae, Biljana Nadjsombati
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20240166628
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: August 2, 2023
    Publication date: May 23, 2024
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE, Biljana NADJSOMBATI
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20240101530
    Abstract: The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 28, 2024
    Inventors: Xiaohu DENG, Stewart JONES, David SLACK
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230382888
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{(6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: October 28, 2021
    Publication date: November 30, 2023
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE, Biljana NADJSOMBATI
  • HDAC inhibitor solid state forms
    Patent number: 11780822
    Abstract: The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: October 10, 2023
    Assignee: VIRACTA SUBSIDIARY, INC.
    Inventors: Xiaohu Deng, Stewart Jones, David Slack
  • HDAC inhibitor solid state forms
    Patent number: 11760748
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: September 19, 2023
    Assignee: VIRACTA SUBSIDIARY, INC.
    Inventors: Xiaohu Deng, Wanping Mai, Robert Mcrae, Biljana Nadjsombati
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230159499
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0 ]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: December 13, 2022
    Publication date: May 25, 2023
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230159494
    Abstract: The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: December 13, 2022
    Publication date: May 25, 2023
    Inventors: Xiaohu DENG, Stewart JONES, David SLACK
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230023953
    Abstract: The present disclosure relates to various solid-state forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. Such forms of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: June 2, 2022
    Publication date: January 26, 2023
    Inventors: Xiaohu DENG, Stewart JONES, David SLACK
  • Synthesis of tipifarnib
    Patent number: 11542244
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 3, 2023
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Pingda Ren, Xiaohu Deng, Wanping Mai
  • METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
    Publication number: 20220226322
    Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
    Type: Application
    Filed: May 28, 2020
    Publication date: July 21, 2022
    Inventors: Robert MCRAE, Gail L. BROWN, Xiaohu DENG, David SLACK, Marshelle Smith WARREN, Richard TRAUGER
  • SYNTHESIS OF TIPIFARNIB
    Publication number: 20210246114
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Application
    Filed: May 17, 2019
    Publication date: August 12, 2021
    Applicant: KURA ONCOLOGY, INC.
    Inventors: Pingda REN, Xiaohu DENG, Wanping MAI
  • Methods of treating virally associated cancers with histone deacetylase inhibitors
    Patent number: 10953011
    Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: March 23, 2021
    Assignee: VIRACTA THERAPEUTICS INC.
    Inventors: Robert McRae, Gail L. Brown, Xiaohu Deng, David Slack, Marshelle Smith Warren, Richard Trauger
  • METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
    Publication number: 20200375990
    Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
    Type: Application
    Filed: July 8, 2020
    Publication date: December 3, 2020
    Inventors: Robert MCRAE, Gail L. BROWN, Xiaohu DENG, David SLACK, Marshelle Smith WARREN, Richard TRAUGER
  • P2X7 modulators and methods of use
    Patent number: 10112937
    Abstract: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 30, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Brett D. Allison, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Xiaohu Deng, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Jimmy T. Liang, Neelakandha S. Mani, Jason C. Rech, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson, Jessica L. Wall
  • Methods for preparation of quinazoline derivatives
    Patent number: 9988357
    Abstract: Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b and R4c, are as defined herein are provided. Related compounds and methods for making the same are also provided.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 5, 2018
    Assignee: Araxes Pharma LLC
    Inventors: Neelakandha S. Mani, Brett D. Allison, Zachary S. Sales, Jimmy T. Liang, Xiaohu Deng, Liansheng Li, Yun Oliver Long, Yuan Liu, Pingda Ren
  • METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES
    Publication number: 20170190672
    Abstract: Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b and R4c, are as defined herein are provided. Related compounds and methods for making the same are also provided.
    Type: Application
    Filed: December 9, 2016
    Publication date: July 6, 2017
    Inventors: Neelakandha S. Mani, Brett D. Allison, Zachary S. Sales, Jimmy T. Liang, Xiaohu Deng, Liansheng Li, Yun Oliver Long, Yuan Liu, Pingda Ren
  • P2X7 MODULATORS
    Publication number: 20160039809
    Abstract: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Manuel Jesus ALCAZAR VACA, Brett D. ALLISON, Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Heather R. COATE, Meri DE ANGELIS, Xiaohu DENG, Curt A. DVORAK, Christine F. GELIN, Michael A. LETAVIC, Jimmy T. LIANG, Neelakandha S. MANI, Jason C. RECH, Brad M. SAVALL, Akinola SOYODE-JOHNSON, Brice M. STENNE, Devin M. SWANSON, Jessica L. WALL
  • Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
    Patent number: 8598202
    Abstract: Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: December 3, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Richard Apodaca, J. Guy Breitenbucher, Alison L. Chambers, Xiaohu Deng, Natalie A. Hawryluk, John M. Keith, Neelakandha S. Mani, Jeffrey E. Merit, Joan M. Pierce, Mark Seierstad, Wei Xiao